Clinical Trial: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Brief Summary: The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).

Detailed Summary:
Sponsor: Innate Pharma

Current Primary Outcome: Occurrence of Dose Limiting Toxicities (DLT) [ Time Frame: Within 2 weeks after the first administration ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Innate Pharma

Dates:
Date Received: October 29, 2015
Date Started: October 2015
Date Completion: December 2019
Last Updated: March 2, 2017
Last Verified: March 2017